False-positive Epo test concerns unfounded / Don Catlin, Gary Green, Michael Sekera, Paul Scott, Borislav Starcevic. - (Blood 108 (2006) 5 (1 September); p. 1778)
- PMID: 16926300
- DOI: 10.1182/blood-2006-03-006890
- Comment on:
False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise / Monique Beullens, Joris R. Delanghe, Mathieu Bollen. - (Blood 107 (2006) 12 (15 June); p. 4711-4713)
-
-
PMID: 16493001
-
DOI: 10.1182/blood-2006-01-0028
-
Abstract for: False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise
Erythropoietin (Epo) is a glycoprotein hormone that promotes the production of red blood cells. Recombinant human Epo (rhEpo) is illicitly used to improve performance in endurance sports. Doping in sports is discouraged by the screening of athletes for rhEPO in urine. The adopted test is based on a combination of isoelectric focusing and double immunoblotting, and distinguishes between endogenous and recombinant human Epo. We show here that this widely used test can occasionally lead to the false-positive detection of rhEpo (epoetin-beta) in postexercise, protein-rich urine, probably because the adopted monoclonal anti-Epo antibodies are not monospecific.
